Drug intelligence / Profile preview

DT-1

Development stage
Unknown
Lead developer
Osaka University
Modality
Monoclonal Antibodies → Antibody-Based Therapeutics
01

Overview

DT-1 is a mouse monoclonal antibody that specifically targets **CD157**, also known as **Bone Marrow Stromal Cell Antigen 1 (BST-1)**. CD157 is a glycosylphosphatidylinositol (GPI)-anchored protein and ectoenzyme (ADP-ribosyl cyclase) expressed on bone marrow stromal cells, synovial nurse-like cells, and certain leukocytes. In the context of **rheumatoid arthritis (RA)**, CD157 on nurse-like cells (NLCs) interacts with B cells to promote their survival and prevent apoptosis. The DT-1 antibody has been used in research to block these interactions, demonstrating the role of CD157 in B-cell hyperreactivity and the pathogenesis of autoimmune diseases. While primarily used as a research tool to characterize BST-1 function, the targeting of CD157 is also being explored in oncology, particularly in acute myeloid leukemia (AML).

Other names
anti-CD157 antibodyanti-CD-157 antibodyanti-CD 157 antibodyanti-BST-1 antibodyanti-BST1 antibodyanti-BST 1 antibody
02

Targets

CD38 (Cluster of Differentiation 38)

Beyond the preview

Go deeper on DT-1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on DT-1.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call